RANCHO CORDOVA, Calif., January 11, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”) will reconvene on Thursday, January 13, 2022 at 12:00 p.m. EST. The meeting, originally scheduled for December 16, 2021, was convened and adjourned without any business being conducted due to … Continued
RANCHO CORDOVA, Calif., January 10, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chief Financial Officer, Jeff Cauble, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. The … Continued
RANCHO CORDOVA, Calif., December 17, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for Thursday, December 16, 2021 at 9:00 a.m. PST, was convened and adjourned without any business being conducted due to lack of the required quorum. A quorum consists of a majority … Continued
Contract Development Manufacturing Organization (CDMO) partnerships are on the rise due to an increased demand for cell therapies and the limited availability of Good Manufacturing Practice (GMP) approved manufacturing facilities and other resources. Pharmaceutical & biotechnology companies are needing to outsource their product development and manufacturing in order to try to meet these demands, even … Continued
Cell separation is an essential part of the manufacturing process for CGT cell therapies like CAR-T. To get the best results, cell samples must be purified and prepared properly. Purifying cells is achieved by a different approaches (positive selection, negative selection, etc.) which all can use different methodologies to accomplish their goals. Some of the … Continued
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., November 12, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2021 … Continued
Cell and gene therapy is growing and new therapies are rapidly evolving , leading to an increase in the demand for efficient and effective cell therapy manufacturing. Each step in the process must be meticulously carried out in order to achieve the best possible results, increasing the likelihood of effectiveness for certain therapies. This begins … Continued
Conference Call to be Held on November 12, 2021 RANCHO CORDOVA, Calif., November 5, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2021 … Continued
Personalized treatments are the wave of the future in medicine. With regenerative medicine treatments like CAR-T cell therapy receiving FDA approval, the demand for the manufacturing of cell therapies is only going to continue to grow. However, there are unique logistical challenges in the cell therapy manufacturing process that are preventing these treatments from becoming … Continued